DarioHealth (NASDAQ:DRIO) Receives “Buy” Rating from Stifel Nicolaus

Stifel Nicolaus reaffirmed their buy rating on shares of DarioHealth (NASDAQ:DRIOFree Report) in a report issued on Monday, Benzinga reports. Stifel Nicolaus currently has a $4.00 price target on the stock.

DarioHealth Trading Down 3.3 %

DRIO opened at $1.48 on Monday. The firm has a market cap of $40.29 million, a P/E ratio of -1.44 and a beta of 1.67. DarioHealth has a 12 month low of $0.68 and a 12 month high of $4.58. The company has a current ratio of 6.93, a quick ratio of 6.26 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average of $1.87 and a 200 day moving average of $1.93.

Institutional Trading of DarioHealth

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in DarioHealth by 20.2% in the fourth quarter. Vanguard Group Inc. now owns 363,042 shares of the company’s stock worth $624,000 after purchasing an additional 61,034 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in DarioHealth by 41.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 105,316 shares of the company’s stock worth $181,000 after purchasing an additional 30,882 shares during the last quarter. Clarity Capital Partners LLC bought a new stake in DarioHealth in the fourth quarter worth about $293,000. Appian Way Asset Management LP lifted its stake in DarioHealth by 2.5% in the fourth quarter. Appian Way Asset Management LP now owns 1,322,444 shares of the company’s stock worth $2,275,000 after purchasing an additional 32,448 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in DarioHealth by 82.1% in the fourth quarter. Northern Trust Corp now owns 73,167 shares of the company’s stock worth $126,000 after purchasing an additional 32,997 shares during the last quarter. Institutional investors own 33.39% of the company’s stock.

DarioHealth Company Profile

(Get Free Report)

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its user-centric multi-chronic condition digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

Featured Stories

Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.